A Northbrook-based maker of an oral testosterone product is planning an initial public offering of 5 million of its shares at an expected price of $11 to $13 a share, according to a filing Monday with the Securities and Exchange Commission.

Clarus Therapeutics Inc. has applied to list its common stock on NASDAQ under the symbol CLRS.

Its two biggest shareholders now are Thomas McNerney & Partners, with a 71 percent stake, and HIG Ventures, with a 25 percent stake. They’ll own 51 percent and 18 percent, respectively, after the offering.

byerak@tribune.com